We are live on ! Find out more
NVO

Novo Nordisk

43.55 USD
-0.37
0.84%
At close Updated Jun 16, 4:00 PM EDT
Pre-market
After hours
43.54
-0.01
0.02%
1 day
-0.84%
5 days
4.51%
1 month
-1.65%
3 months
12.88%
6 months
-11.05%
Year to date
-16.87%
1 year
-43.46%
5 years
4.14%
10 years
68.93%
 

About: With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Employees: 69,500

0
Funds holding %
of 8,096 funds
0
Positive news %
of 84 articles
Price charts implemented using Lightweight Charts™